Oncotype DX(R) predicts 10-year risk of developing metastatic prostate cancer
Genomic Health announced new results from a large multi-center validation study, which confirmed the Oncotype DX® Genomic Prostate Score™ is a strong independent predictor of metastases at 10 years in prostate cancer patients across all National Comprehensive Cancer Network clinical risk groups. March 29, 2017